Adaptimmune Therapeutics plc (ADAP) announced that its strategic collaboration with Roche’s (RHHBY) Genentech has been terminated. Shares of ADAP were down 10% on the news.Both companies collaborated in 2021 to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.The collaboration had two components — the development of allogeneic T-cell therapies for up to five shared cancer targets and the development of personalized allogeneic T-cell therapies.ADAP was responsible fo ...